Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating

Stock News14:20

Jefferies has released a research report highlighting that INNOVENT BIO (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong confidence in achieving its 2027 product sales target of RMB 20 billion and has outlined a 2030 revenue goal of RMB 35 billion to RMB 40 billion, with the majority of this contribution expected from the Chinese market. Additionally, management anticipates a significant rise in global revenue contributions starting in 2030.

Driven by strong revenue growth, INNOVENT BIO is accelerating its global expansion efforts, with three assets—IBI363, IBI343, and IBI324—now advancing to Phase 3 multinational clinical trials (MRCT). In light of these developments, the firm has reiterated its "Buy" rating and lifted its price target from HK$105 to HK$125.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1133409443?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-27 14:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133409443","market":"nz","top_or_hot":-1,"title":"Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating","media":"Stock News","content":"<p>Jefferies has released a research report highlighting that <b>INNOVENT BIO</b> (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong confidence in achieving its 2027 product sales target of RMB 20 billion and has outlined a 2030 revenue goal of RMB 35 billion to RMB 40 billion, with the majority of this contribution expected from the Chinese market. Additionally, management anticipates a significant rise in global revenue contributions starting in 2030.<br><br>Driven by strong revenue growth, <b>INNOVENT BIO</b> is accelerating its global expansion efforts, with three assets—IBI363, IBI343, and IBI324—now advancing to Phase 3 multinational clinical trials (MRCT). In light of these developments, the firm has reiterated its \"Buy\" rating and lifted its price target from HK$105 to HK$125.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Jefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nJefferies Boosts INNOVENT BIO Target to HK$125, Maintains Buy Rating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-27 14:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Jefferies has released a research report highlighting that <b>INNOVENT BIO</b> (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong confidence in achieving its 2027 product sales target of RMB 20 billion and has outlined a 2030 revenue goal of RMB 35 billion to RMB 40 billion, with the majority of this contribution expected from the Chinese market. Additionally, management anticipates a significant rise in global revenue contributions starting in 2030.<br><br>Driven by strong revenue growth, <b>INNOVENT BIO</b> is accelerating its global expansion efforts, with three assets—IBI363, IBI343, and IBI324—now advancing to Phase 3 multinational clinical trials (MRCT). In light of these developments, the firm has reiterated its \"Buy\" rating and lifted its price target from HK$105 to HK$125.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0326950275.SGD","symbol_name":"Schroder ISF China Opportunities A Acc SGD-H","start_time":0,"source_url":"","article_id":"1133409443","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133409443","pubTimestamp":1787811619,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Jefferies has released a research report highlighting that INNOVENT BIO (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK1583":"高瓴概念","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","BK1589":"北水核心资产","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","EWH":"香港ETF-iShares MSCI","01801":"信达生物","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","BK1161":"生物科技","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD"},"translate_title":"杰富瑞将信达生物目标价上调至125港元，维持买入评级","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1,"EWH":1,"KURE":1},"content_text":"Jefferies has released a research report highlighting that INNOVENT BIO (01801) delivered robust sales in the first half of the year, alongside improved profitability. Management has expressed strong confidence in achieving its 2027 product sales target of RMB 20 billion and has outlined a 2030 revenue goal of RMB 35 billion to RMB 40 billion, with the majority of this contribution expected from the Chinese market. Additionally, management anticipates a significant rise in global revenue contributions starting in 2030.Driven by strong revenue growth, INNOVENT BIO is accelerating its global expansion efforts, with three assets—IBI363, IBI343, and IBI324—now advancing to Phase 3 multinational clinical trials (MRCT). In light of these developments, the firm has reiterated its \"Buy\" rating and lifted its price target from HK$105 to HK$125.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.48.0","shortVersion":"4.48.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133409443","isCrawlerRequest":true}